OncoQR ML Revenue

Biotechnology Research • Vienna, Vienna, Austria • 1-10 Employees

OncoQR ML revenue & valuation

Annual revenue	$256,665
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$821,328
Total funding	No funding

Key Contact at OncoQR ML

Geert C. Mudde

Founder and CSO

Company overview

Headquarters	Mooslackengasse 17, Vienna, Vienna 1190, AT
Phone number	+436643733600
Website	oncoqr.com
NAICS	541714
SIC	873
Keywords	Life Science, Cancer Immunotherapy, Cancer Vaccine, Immunooncology, Active Checkpoint Control Immunotherapy, S-Tir (Tm) Technology
Founded	2013
Employees	1-10
Socials

OncoQR ML Email Formats

OncoQR ML uses 2 email formats. The most common is {first initial}.{last name} (e.g., j.doe@oncoqr.com), used 66.7% of the time.

Format	Example	Percentage
{first initial}.{last name}	j.doe@oncoqr.com	66.7%
{first initial}	j@oncoqr.com	33.3%

About OncoQR ML

Privately held OncoQR ML, based in Vienna/Austria, is a pre-clinical biotech company that offers novel therapeutic cancer vaccines based on its unique, proprietary and broadly applicable S-TIR™ (Specific Total Immune Remodeler) technology platform. Unlike any other currently available therapy, the platform is capable of boosting the patient’s immune system to generate a strong, specific and controlled immune response against cancer. This “Active Checkpoint Control Immunotherapy” activates all four naturally available tumour killing mechanisms of the immune system without triggering side effects. The company’s lead candidate OQR100 (TYG100), co-developed with TYG Oncology Ltd. and CR-UK, targets pancreatic cancer and induces neutralizing antibodies against gastrin, a major growth factor for pancreatic- and other forms of gastric cancer. OQR200 is directed against HER2/neu over-expressing breast cancer and induces strong polyclonal humoral (IgG and IgA) and cellular (CD4 and CD8) immune responses, superior to trastuzumab, pertuzumab or passive checkpoint inhibitors. Both lead candidates, which have achieved in vivo Proof of Concept in non-human primates, as well as the S-TIR™ technology platform are now available for out-licensing. For further information visit www.oncoqr.com. + Cancer immunotherapy + Active therapy (protein/peptide based) + Checkpoint Control + No side effects + Activation of all 4 naturally available killing mechanisms of the immune system + Multiple cancer targets

Employees by Management Level

Total employees: 1-10

Seniority

Employees

C-Suite

Employees by Department

OncoQR ML has 1 employees across 1 departments.

Departments

Number of employees

Funding Data

OncoQR ML has never raised funding before.

OncoQR ML Tech Stack

Discover the technologies and tools that power OncoQR ML's digital infrastructure, from frameworks to analytics platforms.

Modernizr

JavaScript libraries

Underscore.js

JavaScript libraries

Google Maps

Maps

Animate.css

UI frameworks

jQuery Migrate

JavaScript libraries

Apache HTTP Server

Web servers

jQuery

JavaScript libraries

PHP

Programming languages

WordPress

Blogs

Yoast SEO

SEO

Cookie Notice

Cookie compliance

GoDaddy

Hosting

Frequently asked questions

OncoQR ML is located in Vienna, Vienna, AT.

You can reach OncoQR ML at +436643733600.

OncoQR ML generates an estimated annual revenue of $256,665. This revenue figure reflects the company's market position and business performance in its industry.

OncoQR ML has an estimated valuation of $821,328. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

OncoQR ML was founded in 2013, making it 13 years old. The company has established itself as a significant player in its industry over this time.

OncoQR ML has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.

Key Contact at OncoQR ML

Geert C. Mudde

Founder and CSO

4.8

40,000 users